Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AMD 3465 hexahydrobromide (GENZ-644494 (hexahydrobromide)) 是一种 CXCR4受体拮抗剂,具有潜在的抗癌和抗 HIV 活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 297 | 现货 | ||
5 mg | ¥ 457 | 现货 | ||
10 mg | ¥ 667 | 现货 | ||
25 mg | ¥ 1,190 | 现货 | ||
50 mg | ¥ 1,780 | 现货 | ||
100 mg | ¥ 2,680 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 571 | 现货 |
产品描述 | AMD 3465 hexahydrobromide (GENZ-644494 (hexahydrobromide)) is a CXCR4 receptor antagonist with potential anticancer and anti-HIV activity. |
靶点活性 | X4 HIV-1 (IIIB):12.3 nM (IC50, in MT-4 cells), HIV-2 (ROD):12.3 nM (IC50, in MT-4 cells), HIV-2 (EHO):12.3 nM (IC50, in MT-4 cells), X4 HIV-1 (NL4.3):6.1 nM (IC50, in MT-4 cells), X4 HIV-1 (HE):9.8 nM (IC50, in MT-4 cells), CXCL12 (AF647)-CXCR4:18 nM (IC50, in SupT1 cells), 12G5 mAb-CXCR4:0.75 nM (IC50, in SupT1 cells), X4 HIV-1 (NL4.3AMD3100):2822 nM (IC50, in MT-4 cells), X4 HIV-1 (RF):7.4 nM (IC50, in MT-4 cells) |
体外活性 | AMD 3465 hexahydrobromide inhibits binding of 12G5 mAb and CXCL12AF647 to CXCR4, with IC50s of 0.75 nM and 18 nM in SupT1 cells.?AMD 3465 (50 nM) totally blocks CXCL12-induced calcium mobilization, with an IC50 of 17 nM, but shows no effect on the intracellular calcium fluxes elicited by the CCR5 ligands RANTES, LD78β and MIP-1β in U87.CD4.CCR5 cells.?AMD 3465 also potently inhibits the replication of X4 HIV strains (IC50: 1-10 nM), but has no effect on CCR5-using (R5) viruses.?AMD3465 is cytotoxic to the X4 HIV-1 strains IIIB, NL4.3, RF and HE with an IC50 ranging from 6 to 12 nM.?The IC50 for suppression of the HIV-2 strains ROD and EHO is 12.3 nM[1].?AMD 3465 inhibits CXCL-12-induced growth in U87 and Daoy cells.?AMD 3465 treatment stimulates the phosphorylation of Erk1/2 in U87 and Daoy cells[2]. |
体内活性 | AMD 3465 with 2.5 mg/kg/d, s.c. for 5 weeks significantly blocks the growth of U87 GBM and Daoy xenografts[2] |
别名 | GENZ-644494 (hexahydrobromide) |
分子量 | 896.07 |
分子式 | C24H44Br6N6 |
CAS No. | 185991-07-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 38 mg/mL (42.41 mM)
DMSO: 50 mg/mL (55.80 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O / DMSO | 1 mM | 1.116 mL | 5.5799 mL | 11.1598 mL | 27.8996 mL |
5 mM | 0.2232 mL | 1.116 mL | 2.232 mL | 5.5799 mL | |
10 mM | 0.1116 mL | 0.558 mL | 1.116 mL | 2.79 mL | |
20 mM | 0.0558 mL | 0.279 mL | 0.558 mL | 1.395 mL | |
DMSO | 50 mM | 0.0223 mL | 0.1116 mL | 0.2232 mL | 0.558 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AMD 3465 hexahydrobromide 185991-07-5 Autophagy GPCR/G Protein Immunology/Inflammation Microbiology/Virology Proteases/Proteasome CXCR HIV Protease Inhibitor AMD-3465 Hexahydrobromide GENZ 644494 AMD3465 GENZ-644494 (hexahydrobromide) HIV AMD 3465 Hexahydrobromide GENZ644494 CXC chemokine receptors GENZ-644494 hexahydrobromide inhibit AMD3465 Hexahydrobromide AMD-3465 AMD 3465 Human immunodeficiency virus GENZ-644494 inhibitor